Position in MLYS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$9,516,627
-$14,517,403 QoQ
Shares Held
352,729
-60.2% QoQ
Ownership
0.399%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#59
of 224 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 99%
Shared 0%
None 1%
Common Shares in MLYS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026D. E. Shaw & Co., Inc. holds $5,017,559,982 across 217 Biotechnology names. MLYS ranks #76 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INSM |
INSMED Inc
|
5,877,959 | $626,707,987 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,104,109 | $332,369,932 | |
| 3 | EXEL |
Exelixis, Inc.
|
5,551,747 | $302,070,554 | |
| 4 | BBIO |
BridgeBio Pharma, Inc.
|
3,633,007 | $270,586,360 | |
| 5 | TGTX |
Tg Therapeutics, Inc.
|
3,400,808 | $186,840,390 | |
| 6 | HALO |
Halozyme Therapeutics, Inc.
|
2,006,479 | $157,047,110 | |
| 7 | AXSM |
Axsome Therapeutics, Inc.
|
604,753 | $148,025,391 | |
| 8 | PTCT |
Ptc Therapeutics, Inc.
|
1,548,919 | $126,345,322 |
All Filings in MLYS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $9,516,627 | 352,729 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $24,034,030 | 887,192 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $41,757,814 | 1,150,670 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $23,166,200 | 610,923 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $7,769,020 | 574,207 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $7,597,468 | 478,430 | Shares | Defined | 2025-05-15 | |
| No filing history on record for this holder in this stock. | ||||||